Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

[Legionella pneumonia after the use of CPAP equipment].

Stolk JM, Russcher A, van Elzakker EP, Schippers EF.

Ned Tijdschr Geneeskd. 2016;160:A9855. Review. Dutch.

PMID:
27096478
2.

Predictors of quality of life in a long-term followup study in panic disorder patients after a clinical drug trial.

Katschnig H, Amering M, Stolk JM, Ballenger JC.

Psychopharmacol Bull. 1996;32(1):149-55.

PMID:
8927665
3.

Long-term follow-up after a drug trial for panic disorder.

Katschnig H, Amering M, Stolk JM, Klerman GL, Ballenger JC, Briggs A, Buller R, Cassano G, Garvey M, Roth M, et al.

Br J Psychiatry. 1995 Oct;167(4):487-94.

PMID:
8829718
4.

Renal metabolism of the beta-subunit of human choriogonadotropin in the rat.

Lefort GP, Stolk JM, Nisula BC.

Endocrinology. 1986 Aug;119(2):924-31.

PMID:
2426095
5.

Effect of physical conditioning on measures of thyroid hormone action.

Caron PJ, Sopko G, Stolk JM, Jacobs DR, Nisula BC.

Horm Metab Res. 1986 Mar;18(3):206-8.

PMID:
3699691
6.

Inheritance of adrenal phenylethanolamine N-methyltransferase activity in the rat.

Stolk JM, Vantini G, Guchhait RB, Hurst JH, Perry BD, U'Prichard DC, Elston RC.

Genetics. 1984 Nov;108(3):633-49.

9.
10.

Serum dopamine-beta-hydroxylase activity in depression and anxiety.

Friedman MJ, Stolk JM, Harris PQ, Cooper TB.

Biol Psychiatry. 1984 Apr;19(4):557-70.

PMID:
6733175
11.
12.

Catecholamine-synthesizing enzymes in paraganglia of aged Fischer-344 rats. Immunohistochemistry and fluorescence microscopy.

Partanen M, Rapoport SI, Reis DJ, Joh TH, Stolk JM, Linnoila I, Teitelman G, Hervonen A.

Cell Tissue Res. 1984;238(2):217-20.

PMID:
6150762
13.

Strain differences in rat brain epinephrine synthesis: regulation of alpha-adrenergic receptor number by epinephrine.

Perry BD, Stolk JM, Vantini G, Guchhait RB, U'Prichard DC.

Science. 1983 Sep 23;221(4617):1297-9.

PMID:
6310752
14.

Phenylethanolamine N-methyltransferase: notes on its purification from bovine adrenal medulla and separation from protein carboxymethyltransferase.

Hurst JH, Guchhait RB, Billingsley ML, Stolk JM, Lovenberg W.

Biochem Biophys Res Commun. 1983 May 16;112(3):1061-8.

PMID:
6847678
15.

Metabolic clearance rate of dopamine beta-hydroxylase in the rat.

Stolk JM, Hurst JH, Guchhait RB, Vantini G, Lefort GP, Nisula BC.

Mol Pharmacol. 1983 Jan;23(1):112-20.

PMID:
6865894
16.

A defect in catecholamine metabolism in kinky-hair disease.

Grover WD, Henkin RI, Schwartz M, Brodsky N, Hobdell E, Stolk JM.

Ann Neurol. 1982 Sep;12(3):263-6. No abstract available.

PMID:
7137961
17.

Regulation and inheritance of dopamine-beta-hydroxylase.

Stolk JM, Hurst JH, Nisula BC.

Behav Genet. 1982 Feb;12(1):37-52.

PMID:
7092762
18.

Circulating dopamine-beta-hydroxylase in the rat: importance of altered disposal pathways in experimental diabetes.

Hurst JH, Nisula BC, Stolk JM.

J Pharmacol Exp Ther. 1982 Jan;220(1):108-14.

PMID:
7031223
19.

The inverse relationship between serum dopamine-beta-hydroxylase activity and thyroid function.

Stolk JM, Hurst JH, Nisula BC.

J Clin Endocrinol Metab. 1980 Aug;51(2):259-64.

PMID:
7400296
20.

Differentiation of adrenomedullary catecholamine synthesizing enzyme responses to repeated immobilization in hybrid rats.

Stolk JM, Harris PQ.

Life Sci. 1980 Jun 16;26(24):2099-104. No abstract available.

PMID:
6104771
21.

Genetic analysis of serum dopamine-beta-hydroxylase activity in rats.

Stolk JM, Hurst JH, Van Riper DA, Harris PQ.

Mol Pharmacol. 1979 Nov;16(3):922-31. No abstract available.

PMID:
530263
22.
23.

Serum dopamine-beta-hydroxylase activity does not reflect sympathetic activation during hypoglycemia.

Nisula BC, Stolk JM.

J Clin Endocrinol Metab. 1978 Oct;47(4):902-5.

PMID:
400734
24.

Depression, hypertension, and serum dopamine-beta-hydroxylase activity.

Friedman MJ, Stolk JM.

Psychosom Med. 1978 Mar;40(2):107-15.

PMID:
652914
25.
26.
27.

Axoplasmic transport of norepinephrine in the rat brain.

Levin BE, Sadowsky CH, Stolk JM.

Life Sci. 1976 Apr 15;18(8):837-40. No abstract available.

PMID:
58362
28.
30.
31.

Social environment and brain biogenic amine metabolism in rats.

Stolk JM, Conner RL, Barchas JD.

J Comp Physiol Psychol. 1974 Aug;87(2):203-7. No abstract available.

PMID:
4279254
32.

A comparison of psychotomimetic drug effects on rat brain norepinephrine metabolism.

Stolk JM, Barchas JD, Goldstein M, Boggan W, Freedman DX.

J Pharmacol Exp Ther. 1974 Apr;189(1):42-50. No abstract available.

PMID:
4823298
33.

Proceedings: Rubidium salts--animal toxicity studies.

Stolk JM.

Psychopharmacol Bull. 1974 Jan;10(1):32-8. No abstract available.

PMID:
4812208
34.

Estimation of in vivo dopamine- -hydroxylase activity in rat brain.

Stolk JM.

J Pharmacol Exp Ther. 1973 Aug;186(2):230-40. No abstract available.

PMID:
4719778
35.

Inhibition of brain dopamine- -hydroxylase activity by methimazole.

Stolk JM, Hanlon DP.

Life Sci II. 1973 May 8;12(9):417-23. No abstract available.

PMID:
4700123
36.

Rubidium-induced increase in shock-elicited aggression in rats.

Stolk JM, Conner RL, Barchas JD.

Psychopharmacologia. 1971;22(3):250-60. No abstract available.

PMID:
5167209
37.

Thyroxine metabolism and thyroid function duing reserpine treatment.

Stolk JM.

Pharmacology. 1971;5(6):351-8. No abstract available.

PMID:
4107547
38.

The effect of parachlorophenylalanine (PCPA) on shock-induced fighting behavior in rats.

Conner RL, Stolk JM, Barchas JD, Dement WC, Levine S.

Physiol Behav. 1970 Nov;5(11):1221-4. No abstract available.

PMID:
4257829
39.

Parachlorophenylalanine and habituation to repetitive auditory startle stimuli in rats.

Conner RL, Stolk JM, Barchas JD, Levine S.

Physiol Behav. 1970 Nov;5(11):1215-9. No abstract available.

PMID:
4257828
41.

Brain norepinephrine: enhanced turnover after rubidium treatment.

Stolk JM, Nowack WJ, Barchas JD, Platman SR.

Science. 1970 Apr 24;168(3930):501-3.

PMID:
5436089
42.

Association of amphetamine toxicity and tissue glycogen depletion in mice and rats.

Stolk JM, Burnett LS, Rech RH.

Arch Int Pharmacodyn Ther. 1970 Apr;184(2):395-404. No abstract available.

PMID:
5453238
43.

Effect of reserpine on accumulation and removal of d-amphetamine- 3 H.

Stolk JM, Rech RH.

Biochem Pharmacol. 1969 Oct;18(10):2786-8. No abstract available.

PMID:
5404008
44.

Enhanced stimulant effects of d-amphetamine in rats treated chronically with reserpine.

Stolk JM, Rech RH.

J Pharmacol Exp Ther. 1968 Sep;163(1):75-83. No abstract available.

PMID:
5673717
45.

Enhanced stimulant effects of d-amphetamine on the spontaneous locomotor activity of rats treated with reserpine.

Stolk JM, Rech RH.

J Pharmacol Exp Ther. 1967 Oct;158(1):140-9. No abstract available.

PMID:
6054074
46.

Species differences in methemoglobin reductase activity.

Stolk JM, Smith RP.

Biochem Pharmacol. 1966 Mar;15(3):343-51. No abstract available.

PMID:
4380376

Supplemental Content

Loading ...
Support Center